Compare Bio-Rad Laboratories, Inc. with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
USD 6,825 Million (Small Cap)
5.00
NA
0.00%
-0.03
8.48%
1.01
Revenue and Profits:
Net Sales:
652 Million
(Quarterly Results - Jun 2025)
Net Profit:
318 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
19.7%
0%
19.7%
6 Months
-12.74%
0%
-12.74%
1 Year
4.26%
0%
4.26%
2 Years
-17.85%
0%
-17.85%
3 Years
-41.43%
0%
-41.43%
4 Years
-50.82%
0%
-50.82%
5 Years
-36.74%
0%
-36.74%
Bio-Rad Laboratories, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
2.18%
EBIT Growth (5y)
2.95%
EBIT to Interest (avg)
30.77
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.06
Sales to Capital Employed (avg)
0.30
Tax Ratio
21.31%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
96.73%
ROCE (avg)
4.97%
ROE (avg)
11.09%
Valuation key factors
Factor
Value
P/E Ratio
5
Industry P/E
Price to Book Value
0.91
EV to EBIT
16.72
EV to EBITDA
10.62
EV to Capital Employed
0.90
EV to Sales
2.21
PEG Ratio
0.07
Dividend Yield
NA
ROCE (Latest)
5.38%
ROE (Latest)
17.30%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Sideways
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bullish
Dow Theory
No Trend
Mildly Bearish
OBV
Mildly Bearish
No Trend
Shareholding Snapshot : Sep 2025
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 106 Schemes (54.41%)
Foreign Institutions
Held by 257 Foreign Institutions (20.77%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
651.60
585.40
11.31%
Operating Profit (PBDIT) excl Other Income
130.10
105.10
23.79%
Interest
12.60
12.00
5.00%
Exceptional Items
332.00
-1.40
23,814.29%
Consolidate Net Profit
317.80
64.00
396.56%
Operating Profit Margin (Excl OI)
122.00%
97.20%
2.48%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 11.31% vs -12.30% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is 396.56% vs 108.94% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
2,566.50
2,671.30
-3.92%
Operating Profit (PBDIT) excl Other Income
503.80
576.20
-12.57%
Interest
48.90
49.40
-1.01%
Exceptional Items
-2,698.80
-1,295.80
-108.27%
Consolidate Net Profit
-1,844.20
-637.30
-189.38%
Operating Profit Margin (Excl OI)
121.20%
143.70%
-2.25%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -3.92% vs -4.67% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -189.38% vs 82.43% in Dec 2023
About Bio-Rad Laboratories, Inc. 
Bio-Rad Laboratories, Inc.
Pharmaceuticals & Biotechnology
Bio-Rad Laboratories, Inc. manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate chemical and biological materials and to identify, analyze and purify their components. The Company operates through two segments: Life Science and Clinical Diagnostics. Life Science segment markets and develops, manufactures and markets approximately 6,000 reagents, apparatus and laboratory instruments. Its products are used in research techniques, biopharmaceutical production processes and food testing regimes. Clinical Diagnostics segment designs, manufactures, sells and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market.
Company Coordinates 
Company Details
1000 ALFRED NOBEL DR , HERCULES CA : 94547-1811
Registrar Details






